Scientists today are looking to develop the next generation of drug delivery technologies, hoping to ensure novel treatments can effectively reach patients by optimizing the design, properties, analysis, formulation and delivery of new medicines and therapies.
Register now so as not to miss out on what will be an exciting event with plenty of insights about where drug delivery is heading.
The webinar is being run by BioPharma-Reporter in collaboration with our sister site, Outsourcing-Pharma. Broadcasting live on May 5 at 10am CT (Chicago), 5pm CET (Paris), the hour long broadcast involves a top notch panel of experts.
Gene therapy delivery
We are honored to be joined by Annette Bak, head of advanced drug delivery, pharmaceutical sciences R&D, AstraZeneca. In her role with that pharma giant, she has been instrumental in delivering new modality formulations for clinical studies, most notably vascular endothelial growth factor (VEGF) mRNA currently evaluated for cardiac regeneration, building intracellular drug delivery capabilities, and sponsoring initiatives on augmenting drug discovery with AI.
Bak will be talking about innovations in gene therapy drug delivery, in particular the use of nanoparticle technology to get large molecules into the cell - in other words a non-viral vector approach.
Oral biologics
Also presenting next week is Ravi Srinivasan, CEO of i20 therapeutics. He co-founded i2O Therapeutics, whose mission is to develop oral biologics. He will discuss the development of safe and effective oral formulations of therapies traditionally limited to injections.
Srinivasan has a track record in leading companies from inception to exit and developing products from concept through commercialization. His therapeutic areas of interest and experience are oncology, dermatology, ophthalmology, and diabetes.
Emerging trends
We are delighted to report that Sven Stegemann, professor for patient centric drug product development at Graz University of Technology in Austria, is also part of our panel of experts. During his 28-year career in the industry, he has advised pharma firms on ways to improve formulation design, development, and manufacture of pharmaceutical products, including advanced drug delivery and manufacturing technologies and controls. He will be discussing drug delivery developments to date, emerging trends, and challenges.
Inhalable therapies
And last, but certainly not least, we will be joined by Robert O Williams III, professor in the division of molecular pharmaceutics, and drug delivery head, at the College of Pharmacy at the University of Texas. His lab’s research focuses on efforts to enhance solubility and dissolution via novel particle engineering technologies. In 2019, the National Academy of Inventors named him a fellow for his body of work. He will be talking about a thin film freezing (TFF) platform, which is designed to turn more molecules into inhalable therapies.
The speakers' presentations will be followed by a live Q&A session whereby you, the audience, can put your questions to the panel, so register now to participate.
